 |
 |
Recently published review of Azilect clinical trial (Adagio) in the lancet.neurology (Vol 8 December 2009, )found that while it used an interesting trial design, this study didn't end the uncertainty over whether Azilect offers neuroprotection and to whom. "ADAGIO misses a beat?" by Karl Kieburtz, Lancet Neurology, dec. 2009. excerpt: " Uncertainty is not a satisfying result. The results of this study1 and TEMPO2 will certainly lead some clinicians to use rasagiline for its known symptomatic benefi t and the possibility of slowing PD disease progression. Other clinicians will use established PD therapies (eg, levodopa) that also have some hint of slowing PD progression and are less costly. The uncertainty should be settled by further investigation of both the 1 mg dose and the 2 mg dose, learning from the lessons of previous studies. Although the investigators should be congratulated for a considerable research accomplishment, the implications for patient care remain uncertain." I was prescribed .5 mil/day, as an adjunct to levodopa. but I haven't noticed any symptom improvment . I'm am hoping it truly is neuroprotective,even at this lower dose. (higher than .5 mil increased dyskinesia. ) Seems the jury is still out.... linda ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn